Transcolonic Therapy: A New Frontier in Gut Infection Treatment

When you take an antibiotic tablet for a gut infection, you might reasonably assume that the medication goes directly to where the infection is. The reality is very different. Oral antibiotics are absorbed through the stomach and small intestine into the bloodstream. They are distributed throughout the entire body, metabolised by the liver, and only a fraction of the original dose ultimately reaches the colon — where the parasites actually live.

This pharmacokinetic reality explains why oral antibiotics, while often effective, have significant limitations for treating colonic infections. It also explains why transcolonic antibiotic infusion — delivering medication directly to the site of infection — represents such a compelling advance.

The Problem with Oral Antibiotics for Colonic Parasites

Intestinal parasites like Dientamoeba fragilis and Blastocystis hominis live within the colonic lumen. They do not invade the bloodstream. They reside in the mucosal environment of the large intestine, which is precisely the location that oral antibiotics reach least efficiently.

After oral ingestion, antibiotics undergo first-pass metabolism in the liver, where a significant proportion of the drug is broken down before it even reaches the systemic circulation. The fraction that does reach the bloodstream is distributed across all body tissues, with only a small portion filtering back into the colonic lumen. The result is that drug concentrations at the actual site of infection may be subtherapeutic — high enough to disrupt the gut microbiome and cause side effects, but not high enough to reliably eradicate the target organism.

This explains the roughly 75 percent eradication rate achieved with oral therapy for these parasites. It is a respectable number, but it means that one in four patients will complete a full antibiotic course — with all its attendant side effects — and still have the infection. For patients who fail multiple courses of oral therapy, the experience becomes deeply demoralising.

The Logic of Transcolonic Delivery

Transcolonic antibiotic infusion takes a fundamentally different approach. Rather than relying on systemic absorption and redistribution, the medication is delivered directly into the colon through a colonoscopic procedure. This allows the antibiotic to be placed exactly where it is needed — in the colonic lumen, at concentrations that far exceed what oral dosing can achieve.

The pharmacological advantages are substantial. Local drug concentrations can be ten to fifty times higher than those achieved through oral delivery. Because the medication acts locally rather than systemically, systemic side effects are dramatically reduced. Patients experience fewer of the nausea, diarrhoea, and dysbiosis that commonly accompany oral antibiotic courses.

The procedure itself is performed as a day case under light sedation, similar to a standard diagnostic colonoscopy. The antibiotic solution is infused directly into the colon, where it bathes the mucosa and comes into direct contact with the parasites. The entire procedure typically takes less than 30 minutes.

The Results: 98 Percent Success

Our clinic has achieved a 98 percent eradication rate for Dientamoeba fragilis and Blastocystis hominis using transcolonic antibiotic infusion in patients who have failed oral therapy. This compares to approximately 75 percent with oral treatment alone.

These numbers tell a powerful story about the importance of drug delivery. The same antibiotics, delivered directly to the site of infection at appropriate concentrations, achieve dramatically better results than when filtered through the entire body first. It is the same principle that drives localised chemotherapy, intravitreal injections in ophthalmology, and direct wound irrigation in surgery — targeted delivery outperforms systemic delivery for localised disease.

The clinical improvement following successful eradication is often rapid and dramatic. Bloating resolves. Energy returns. Brain fog clears. Bowel habits normalise. For patients who have been symptomatic for months or years, the transformation can be profound.

Who Is a Candidate for Transcolonic Therapy?

Transcolonic antibiotic infusion is not our first-line treatment — we reserve it for patients who have confirmed parasitic infection and have failed at least one adequate course of oral therapy. For the majority of patients, oral treatment with secnidazole, paromomycin, or nitazoxanide is effective, well tolerated, and the appropriate first step.

However, for the substantial minority who do not respond to oral treatment — and for patients with recurrent infection despite apparently successful initial eradication — transcolonic infusion offers a definitive solution. It is also an attractive option for patients who experience significant side effects from oral antibiotics and prefer a more targeted approach.

The Broader Principle: Targeted Therapy

Transcolonic antibiotic infusion exemplifies a broader principle that is increasingly shaping modern gastroenterology: the recognition that the gut is not a passive tube through which medications happen to pass, but a complex organ system that requires targeted, site-specific intervention.

Just as FMT delivers beneficial bacteria directly to the colon to restore the microbiome, transcolonic antibiotic infusion delivers antimicrobial agents directly to the colon to eradicate pathogens. Both approaches leverage the same insight — that for conditions affecting the colon specifically, direct colonic delivery is more effective than systemic therapy.

This principle extends beyond parasitic infection. We are applying similar targeted delivery strategies for other colonic conditions, always guided by the same logic: deliver the right treatment to the right location at the right concentration.

The pharmacological rationale is robust. When Dientamoeba fragilis or Blastocystis hominis reside in the colonic mucosa, they are bathed in concentrations of oral antibiotics that are often subtherapeutic. Because the parasite lives in a local microenvironment — the mucus layer and epithelial surface — delivering medication directly to that site achieves concentrations that would be toxic if achieved systemically. This is why transcolonic infusion achieves 98 percent eradication compared to 75 percent with oral therapy — not because the drugs are different, but because the delivery method is optimised for the target location.

This principle has broader applications beyond parasitic infection. Similar transcolonic approaches are being explored for inflammatory bowel disease, recurrent C. difficile infection, and other colonic conditions. The recognition that direct delivery to the target site is more effective than systemic therapy is reshaping how we approach colonic disease management.

For patients with recurrent parasitic infection despite apparently successful eradication, we investigate possible reinfection sources. Household contacts should be tested if results are positive in the index patient. Pets may occasionally harbour transmissible parasites, though evidence varies by species. Environmental hygiene and hand-washing protocols are reinforced, particularly after toileting and before eating. Some patients who have completed treatment and recovered later report recurrence — in these cases, reinfection rather than treatment failure is usually the cause, and we repeat evaluation with the same rigorous testing protocols.

Safety and Practical Considerations

Transcolonic antibiotic infusion has an excellent safety profile. The procedure carries the same low-level risks as any colonoscopy — a very small risk of bleeding or perforation — but the addition of antibiotic infusion does not significantly increase these risks. Recovery is quick, and most patients return to normal activities the following day.

Pre-procedure preparation follows standard colonoscopy protocols, including bowel preparation the day before. We provide detailed instructions and support to ensure patients are fully prepared and comfortable with the process.

The procedure itself takes 20 to 30 minutes under light sedation. The colonoscope is advanced to the caecum or ascending colon, the antibiotic solution is infused directly through the scope, and the patient is then allowed to rest in recovery before discharge. Many patients experience marked symptom improvement within days — the bloating and discomfort that followed oral antibiotic courses often does not occur after transcolonic delivery, because the drug acts locally without significantly disrupting the rest of the microbiome.

For patients who have suffered through multiple failed treatments, the psychological relief of achieving 98 percent eradication rates with a single targeted procedure is profound. After months or years of hope followed by disappointment, a definitive solution provides closure and allows life to move forward.

Delivering antibiotics directly to where the parasites live — rather than hoping enough medication survives the journey through the bloodstream — is a simple concept with transformative results.

If you have been diagnosed with Dientamoeba fragilis or Blastocystis hominis and oral treatment has not worked, transcolonic antibiotic infusion may be the answer. With a 98 percent success rate and a favourable side-effect profile, it represents the most effective option available for refractory parasitic gut infections.